Worth reading
43Recurring
Scored from 5 of 6 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Announced details
Launch date9 September 2026 (actual publication start date)
Relationship between the counterparty and the company
Oncolys BioPharma Inc.4588
Relationship with the Company
フェアリサーチ社 prepared and published an analyst report on the Company. Capital and personnel relationships are Not disclosed.
Counterpartyフェアリサーチ社
A third-party company that prepared the analyst report. Other information, including its location, representative and business activities, is Not disclosed.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Source (materials cited by the company)
フェアリサーチ社
| Item | Details |
|---|---|
| Counterparty | フェアリサーチ社 |
| Counterparty overview | A third-party company that prepared the analyst report. Other information, including its location, representative and business activities, is Not disclosed. |
| Relationship with the Company | フェアリサーチ社 prepared and published an analyst report on the Company. Capital and personnel relationships are Not disclosed. |
| Launch date | 9 September 2026 (actual publication start date) |
| Source | フェアリサーチ社 |
Items this document does not state (13)
Names of Products / Services CoveredContract ValueOffering priceContract DateApplicable areaAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historyImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To publish a report based on research and analysis from a third-party perspective and deepen stakeholders’ understanding of our business.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.